Richard Norton’s Death Passed Every Check in Australia’s Peptide System

“I am not satisfied that it is appropriate for them to be available to be prescribed by medical practitioners.” Victorian Coroner David Ryan wrote that sentence about CJC-1295 and ipamorelin, the two unapproved peptides injected by the Australian actor Richard Norton in the days before his death. Norton, 75, died at Melbourne’s Alfred Hospital on 30 March 2025, and Ryan found that his death was triggered by the injection. The prescription had passed through the system’s checks, one by one, and each of them had signed off.

Norton was a martial artist, stunt performer and fight choreographer whose screen career ran from the 1980 film The Octagon to Mad Max: Fury Road, where he played the Prime Imperator, and who had worked as a bodyguard to touring acts including David Bowie. In March 2025 he went to Dr Jerzy Muchnicki seeking peptide therapy for fatigue, shoulder pain, slower physical recovery and loss of lean muscle mass, symptoms for which another practitioner had previously prescribed him peptides. CJC-1295 and ipamorelin stimulate the body’s own growth hormone production and are promoted for muscle growth, recovery and anti-ageing. Neither product is listed on the Australian Register of Therapeutic Goods, which means the Therapeutic Goods Administration (TGA) has never evaluated either one for safety, quality or effectiveness.

The first check was the conversation itself. Norton and Muchnicki discussed the experimental nature of the treatment in detail, including its potential risks and the fact that no TGA-approved alternatives existed for what he wanted treated. Blood tests were run to confirm his baseline health and to look for contraindications, and a CT artery calcium score was done before anything was prescribed. Norton signed an informed-consent form that set out the treatment, its benefits and its risks, and anaphylaxis was among the risks it named. He was prescribed CJC-1295 and ipamorelin injections on 19 March, and a week later he told the clinic he was feeling good and that the therapy was improving his symptoms. On 28 March he told a nurse he had been taking double the prescribed doses. She told him to take only the prescribed dose from the following week, the doctor prescribed two further peptides to improve function and reduce pain, and hours later, after injecting CJC-1295 and ipamorelin, Norton felt hot and flushed and became unresponsive. He suffered a cardiac arrest, and the conditions listed around his death included asthma and hypertrophic cardiomyopathy.

The Medical Board of Australia investigated after the Australian Health Practitioner Regulation Agency received a notification about Muchnicki’s treatment of Norton. Its independent expert, clinical professor Alistair Vickery, found there was insufficient evidence that CJC-1295 or ipamorelin is safe, effective or beneficial for human use, and he described Muchnicki’s notes as sparse, inadequate and perfunctory. Vickery also weighed the doctor’s training and experience, Norton’s written consent and his earlier peptide use without adverse effects, and on that balance he judged the clinical care reasonably up to the expected standard while the record-keeping fell below it. In its July decision the board found Muchnicki’s practice is or may be unsatisfactory, decided that regulatory action was not warranted, and imposed a caution, conditions and one-on-one education in clinical record-keeping and management.

Norton’s injections were made by a compounding pharmacy in Queensland operating under licence. Compounding exists so a pharmacist can prepare a medicine for an individual patient, and the TGA told the ABC that different pathways exist through which practitioners can access unapproved peptides. It also told the ABC that it is still assessing the risks and whether additional regulatory or other measures are appropriate. The checks in Norton’s case examined the doctor, the consent and the pharmacy. The product itself had never been through the evaluation those checks exist to stand in for.

Ryan’s recommendation is aimed at the product rather than the people. He asked the TGA to review the therapeutic benefits and safety risks of the peptides and to consider whether further restrictions ought to be imposed on their use, including, as the Guardian’s report of the findings details, moving them from Schedule 4 to Schedule 10. Schedule 4 is prescription-only medicine. Schedule 10, under the national Poisons Standard, covers substances of such danger to health as to warrant prohibition of sale, supply and use. A recommendation is not a ban, and the decision sits with the TGA, but the Coroners Court of Victoria’s own rules give that decision a clock: a public statutory authority that receives a coronial recommendation must respond in writing within three months, stating what action, if any, has or will be taken.

Victoria’s chief health officer had already put the wider pattern on the record the day before the findings were handed down. Dr Caroline McElnay’s health advisory of 27 October 2026 reports 13 anaphylaxis cases associated with unapproved peptides notified in Victoria since July 2025, including a cluster of five in the second half of September 2026 and two more in October to date. All but one of those patients had never experienced anaphylaxis before, and some only reacted after several uneventful doses. McElnay urged clinicians to have open, non-judgemental discussions with patients about peptide use and to advise them of the very real risk of anaphylaxis and the need for immediate care if symptoms develop.

New South Wales published the same pattern at hospital scale nine days earlier. NSW Health figures released on 19 October 2026 show 1,180 emergency-department presentations associated with unapproved peptides between 1 July 2025 and 30 September 2026, rising from five presentations in July 2025 to 217 in September 2026. Retatrutide, an experimental obesity drug, accounted for 71 percent of the presentations, and Hunter New England recorded 86 over the 15 months. Health Minister Ryan Park warned that the products could cause liver and kidney damage, allergic reactions and severe vomiting. These are mostly online-sourced products, not prescribed compounded injections like Norton’s, and the two supply routes should not be blurred. What they share is the status that made Norton’s case possible: unapproved, and never evaluated.

Australia has already used a regulatory lever against a neighbouring part of this market, and the contrast shows what the coroner is and is not asking for. In May 2024, Health Minister Mark Butler announced that GLP-1 receptor agonists would be removed from the pharmacy compounding exemption from 1 October 2024, after about 20,000 Australians were injecting compounded replicas of weight-loss drugs. Compounded products, the government’s release said, are not clinically evaluated by the TGA for safety, quality or effectiveness. That move closed an exemption for copies of approved drugs. Ryan is asking the TGA to consider a different lever, rescheduling, for products that were never approved in the first place. The TGA and the Chief Medical Officer had already warned together on 19 June 2026 that unapproved peptides were linked to liver damage, severe allergic reactions requiring hospitalisation and inflammation, and on 20 July the TGA warned suppliers and promoters that unlawful advertising, importing, manufacturing and supply could trigger enforcement action.

Independent MP Dr Monique Ryan renewed her call for a parliamentary inquiry into online telehealth, arguing that the system itself is the problem. “The system allowed it,” her statement said, adding that the TGA regulates products and the Australian Health Practitioner Regulation Agency oversees doctors, while nobody regulates the business models driving the market. Her inquiry would examine vertically integrated telehealth, pharmacy and retail models and the gaps in responsibility between the TGA, the practitioner regulator and the states. The Medical Republic, reporting her call, noted that the coroner’s report on Norton’s death contains no mention of telehealth at all.

Muchnicki accepted the criticisms and expressed sorrow for the impact on Norton and his family. He swore off prescribing peptides unless robust clinical evidence supported them.